

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities in the Company.



Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

COMPLETION OF ISSUE OF CONVERTIBLE NOTES UNDER GENERAL MANDATE

Reference is made to the announcement of Jacobson Pharma Corporation Limited (the “**Company**”) dated 6 September 2017 in relation to, among other matters, the proposed issue of Convertible Notes under the General Mandate (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

COMPLETION OF THE SUBSCRIPTION

The Board is pleased to announce that all the conditions to the Subscription Agreements have been fulfilled and that the Convertible Notes in the principal amount of HK\$500,000,000 have been issued by the Company to the Subscribers on 3 October 2017. Dragons has subscribed for the Convertible Notes in a principal amount of HK\$280 million and HH JP has subscribed for the Convertible Notes in a principal amount of HK\$220 million. Based on the initial Conversion Price of HK\$2.50 per Conversion Share, a maximum number of 200,000,000 Shares, representing approximately 11.02% of the existing issued share capital of the Company as at the date of this announcement and approximately 9.92% of the issued share capital of the Company as enlarged by the allotment and issue of the Conversion Shares, will be allotted and issued upon exercise of the Conversion Rights attached to the Convertible Notes in full. The approval for the listing of, and the permission to deal in, the 200,000,000 Conversion Shares upon conversion of the Convertible Notes has been granted by the Stock Exchange.

The net proceeds arising from the issue of the Convertible Notes, after deduction of expenses, amounts to approximately HK\$490,000,000, which shall be used for funding potential merger and acquisitions as well as forming strategic alliances in the Asia Pacific region. The proceeds will also be used for supporting in-licensing and direct investment on technologically-oriented bio-pharmaceutical projects.

By order of the Board of
Jacobson Pharma Corporation Limited
WU Lai King
Company Secretary

Hong Kong, 3 October 2017

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Dr. Lam Kwing Tong, Alan, Professor Chow Hee Lum, Albert and Mr. Young Chun Man, Kenneth as independent non-executive Directors.